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Abbreviations
and Acronyms
AF = atrial ﬁbrillation
Ca2þ = calcium
DAD = delayed
afterdepolarizations
EAD = early
afterdepolarizations
HCM = hypertrophic
cardiomyopathy
JMC = junctional membrane
complex
JPH2 = junctophilin-2
þ 2þ
JACC Vol. 62, No. 21, 2013 Beavers et al.
November 19/26, 2013:2010–9 Role of Junctophilin in Atrial Fibrillation
2011and delayed afterdepolarizations (DADs) (2,3). Spontaneous
diastolic Ca2þ release from the sarcoplasmic reticulum (SR)
generates a depolarizing Naþ/Ca2þ exchanger (NCX) current,
which may induce DADs and triggered activity (4). The major
SR Ca2þ release channel responsible for arrhythmogenic Ca2þ
release is the type 2 ryanodine receptor channel (RyR2) located
within junctional membrane complexes (JMCs) (5–7). Defec-
tive regulation and activity of RyR2 has been linked to AF in
humans and various animal models (4,8,9). In addition, struc-
tural changes in the JMC may precipitate destabilization of
RyR2 and diastolic Ca2þ leakage (10). However, the molecular
mechanisms underlying abnormal RyR2 Ca2þ leakage from
JMCs remain poorly understood, especially in the atrial
myocardium.See page 2020
NCX = Na /Ca exchanger
NTg = nontransgenic
PKI = pseudoknock-in
RyR2 = ryanodine receptor
type 2
SR = sarcoplasmic reticulum
Tg = transgenic
WT = wild typeJunctophilin-2 (JPH2) plays a critical structural role
within JMCs (10,11). In mouse studies, knockdown of
JPH2 was associated with loss of JMC numbers, reduced
Ca2þ-induced Ca2þ release, and development of acute heart
failure (10). Several mutations in JPH2 were previously
identiﬁed in patients with hypertrophic cardiomyopathy
(HCM) (12,13). Here, we report two novel JPH2 muta-
tions, one of which, E169K, was identiﬁed in a proband
with the unusual clinical presentation of juvenile-onset
paroxysmal AF (pAF). The proband’s father, carrying the
same mutation, also exhibited supraventricular tachycardia in
addition to HCM. The patient with the other HCM-
associated JPH2 mutation, A405S, did not exhibit atrial
arrhythmias, similar to all other previously reported HCM
patients with JPH2 mutations (12,13).
To determine how the E169K mutation in JPH2 might
cause atrial arrhythmias, we generated genetically modiﬁed
mouse lines carrying the E169K or A399S (A405S in
humans) mutation in JPH2. Subsequently, pseudoknock-in
(PKI) mice with total cardiac JPH2 levels similar to those of
nontransgenic (NTg) mice were generated by crossing JPH2
transgenic (Tg) mice with inducible, cardiac-speciﬁc JPH2
knockdownmice. TheE169K-PKI but notA399S-PKImice
exhibited an enhanced susceptibility to pacing-induced AF.
Atrial myocytes from E169K-PKI but not A399S-PKI mice
showed an increased frequency of spontaneous SR Ca2þ
release events. Interestingly, the JPH2 E169K mutation
but not the A399S mutation decreased the binding afﬁnity
of JPH2 to RyR2. To further examine the importance of
JPH2 loss-of-function in AF, atrial JPH2 levels in mice were
shown to have an inverse correlation with AF inducibility.
Addition of a small peptide containing the E169 region of
JPH2 was able to ameliorate the Ca2þ spark frequency in
atrial cardiomyocytes isolated from JPH2 knockdown mice,
and to normalize the open probability (Po) of RyR2 chan-
nels from JPH2 knockdown mice. Finally, to assess the
importance of JPH2 in clinical AF, JPH2 protein levels were
assessed in atrial samples from non-HCM patients withpAF. JPH2:RyR2 ratios were
reduced signiﬁcantly in pAF pa-
tients compared with those in
sinus rhythm, and isolated atrial
cardiomyocytes showed an in-
creased frequency of potential
proarrhythmic SR Ca2þ release
events, consistent with enhanced
RyR2 activity.
Together, these data suggest
that reduced JPH2-mediated
stabilization of RyR2 (either
because of the unique inherited
loss-of-function E169K muta-
tion in JPH2 or because of the
reduced JPH2 expression levels
per RyR2 channel) can promote
abnormal RyR2-mediated SR
Ca2þ release events associated
with AF. These ﬁndings may
open new avenues for the de-
velopment of anti-AF drugs
that target either JPH2 or RyR2
abnormalities, to reduce spontaneous proarrhythmic dia-
stolic SR Ca2þ release events.
Methods
Expanded methods can be found in the Online Appendix.
Genetic analysis. Comprehensive encoding region genetic
analysis of JPH2 was accomplished by polymerase chain
reaction, denaturing high performance liquid chromatog-
raphy, and direct DNA sequencing as described previously
(12).
Generation of animals. All animal studies were performed
according to protocols approved by the Institutional Animal
Care and Use Committee of Baylor College of Medicine,
conforming to the Guide for the Care and Use of Laboratory
Animals published by the U.S. National Institutes of Health
(NIH publication 85-23, revised 1996). Generation of Tg
mice, including the WT-Tg and E169K and A399S JPH2
mutant Tg and short hairpin RNA (shRNA) knockdown
mice, is described in detail in the Online Appendix.
Pseudoknock-in mice were generated by crossing the JPH2
Tg mice (WT and E169K and A399S mutants) with an
inducible cardiac-speciﬁc JPH2 knockdown mouse line. The
offspring were given doses of tamoxifen to induce shRNA-
mediated knockdown of total JPH2 levels to protein levels
similar to those in NTg mouse hearts. Experiments were
performed between 2 and 3 weeks post-knockdown when
JPH2 levels were stable.
Programmed electrical stimulation. Atrial and ventricular
intracardiac electrocardiography (ECG) traces were recorded
using a 1.1F octapolar electrode catheter (EPR-800, Millar
Instruments, Houston, Texas) inserted into the right ventricle
via the right jugular vein, as described previously (14). Atrial
Figure 1 E169K-JPH2 Is Associated With HCM and pAF
Pedigree shows presence of HCM and supraventricular arrhythmias (pAF, SA block, SVT) in proband (arrow) and his father (gray square), both of whom were mutation positive
(heterozygous G > A), and his sister, who was genotype negative (white circle), as indicated by the asterisk. HCM ¼ hypertrophic cardiomyopathy; pAF ¼ paroxysmal atrial
ﬁbrillation; SA ¼ sinoatrial; SVT ¼ supraventricular tachycardia.
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2012ﬁbrillation inducibility was determined using rapid atrial
pacing; AF was considered positive only if it lasted for 1 s.
Mouse myocyte isolation and confocal Ca2D imaging.
Mouse atrial myocytes were isolated and loaded with the
Ca2þ-sensitive dye Fluo-4 AM (Invitrogen, Eugene, Ore-
gon) as described previously (9). Once steady-state Ca2þ
transients were observed, pacing was paused for 30 s to
record spontaneous Ca2þ release events (Ca2þ waves and
Ca2þ sparks). Steady-state SR Ca2þ was estimated by rapid
application of 10 mM of caffeine after pacing.
Simultaneous intracellular Ca2D and membrane current
measurements in human atrial myocytes. Right atrial
biopsy samples were dissected from appendages of patients
with pAF or those in sinus rhythm who underwent coronary
artery bypass or valve replacement surgery. Protocols were
approved by the medical ethics committees of the Dresden
University of Technology and the Medical Faculty Man-
nheim, University of Heidelberg, Germany.
Statistical analyses. Results are expressed as mean 
standard error of the mean. Normality was examined using
the Shapiro-Wilk test. Continuous variables with normal
distribution were compared using analysis of variance with
a post-hoc Tukey test for equal variance and Dunnett’s T3
test for unequal variance, and paired samples were analyzed
using a paired Student t test. Continuous variables that
failed the test of normality were compared using the
Kruskal-Wallis test, and pairs of data were analyzed using
the Mann-Whitney test. Ordinal variables were compared
using the Kendall tau B coefﬁcient. Categorical variables
were compared using the Pearson chi-square test, and pairs
of data were examined with the Fisher exact test. A
p value <0.05 was considered statistically signiﬁcant.
Results
Identiﬁcation of the JPH2 E169K mutation in patients
with HCM and AF. Previous studies have demonstrated
the presence of rare, functionally disruptive JPH2 muta-
tions in patients with HCM (12,13). Analyzing JPH2 formutations in an independent cohort of 203 unrelated
patients with HCM revealed a new missense mutation
annotated as E169K in a male index case with unusually
early onset paroxysmal AF in the context of HCM (Fig. 1).
This JPH2 genotype-positive patient was negative for
mutations in the 9 canonical sarcomeric HCM-associated
genes. Diagnosed with HCM at 5 months of age, this
patient went on to develop profound septal hypertrophy
(32 mm) with marked diastolic dysfunction and labile left
ventricular outﬂow obstruction (Online Fig. 1). The onset
of pAF was documented at the young age of 22 prior
to signiﬁcant atrial remodeling. At age 24, he required
pacemaker implantation due to paroxysmal sinoatrial (SA)
blocks and pre-syncope. Clinical and genetic evaluation of
family members revealed the E169K mutation in the
proband’s father, who had HCM with 15 mm maximal left
ventricular thickness and paroxysmal supraventricular
tachycardia during clinical evaluation blinded to genotype
(Fig. 1). In contrast, the proband’s sister was mutation-
negative and had a normal cardiac work-up. Both the
proband and his father had prolonged QTc intervals,
whereas the sister’s QTc was normal (Online Fig. 1). No
other family members were available for genetic testing. In
the same cohort, another JPH2 variant (A405S) was
identiﬁed in a Caucasian male whose HCM was diagnosed
at age 16 years. This proband presented with dyspnea,
chest pain, and dizziness. He later developed basal septal
morphology hypertrophy (23 mm) and was diagnosed with
HCM. He had no family history of HCM or sudden
cardiac death; both parents were genotype negative and
never developed QTc prolongation or supraventricular
arrhythmias.
E169K-PKI mice are more susceptible to AF induction.
The unusual association of atrial arrhythmias with HCM
in the 2 patients with the E169K mutation in JPH2
prompted further mechanistic analysis in animal models. In
order to create a model resembling the heterozygous disease
state of patients, we generated PKI mice that expressed
hemagglutinin-tagged E169K mutant JPH2 (E169K-PKI),
Figure 2 Higher Susceptibility to Pacing-Induced AF in E169K-PKI But Not A399S Mice
(A) Representative ECG traces after rapid atrial burst pacing in E169K-PKI mouse reveal AF compared with sinus rhythm in WT-PKI and A399S-PKI mice. (B) Graph shows
average duration of AF episodes following rapid atrial pacing bursts. Number of occurrences are shown inside bars. (C) Graph shows increased incidence of pacing-induced AF
(reproducible and lasting >1 s) in E169K-PKI mice compared with WT-PKI and A399S-PKI mice. Numbers of mice per group are shown inside bars. *p < 0.05. AF ¼ atrial
ﬁbrillation; ECG ¼ electrocardiography.
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2013wild-type JPH2 (WT-PKI), or A399S (A405S in humans)
mutant JPH2 (A399S-PKI). The total (i.e., combined
endogenous and transgenic) cardiac JPH2 levels in these
WT and mutant PKI mouse lines were similar to those in
NTg littermates (Online Fig. 2), whereas approximately half
of the JPH2 in PKI mice was mutant/transgenic and the
other half endogenous JPH2.
To determine whether the E169K mutation in JPH2
increased susceptibility to AF, we subjected E169K-PKI
mice to programmed electrical stimulation at an age prior
to the onset of cardiac hypertrophy or dysfunction (Online
Fig. 3) (8). Following a rapid atrial burst pacing sequence,
E169K-PKI mice exhibited a higher incidence of AF than
WT-PKI and A399S-PKI mice (Fig. 2A). The average
duration of AF episodes in E169K-PKI mice was 3.9  2.1 s,
whereas the duration of (nonreproducible) AF episodes in
WT-PKI mice was only 0.6  0.6 s (p < 0.05 vs. E169K-
PKI) and 0.2  0.2 s for A399S-PKI (p ¼ 0.06 vs. E169K-
PKI) (Fig. 2B). The longest episode of pacing-induced AF
recorded in an E169K-PKI mouse was 29 s. The incidence
of reproducible AF (deﬁned as 2 episodes of AF per 3
attempts) was 60% in E169K-PKI mice, whereas it was 0%
in WT-PKI mice (p < 0.05 vs. E169K-PKI) and 0% in
A399S-PKI mice (p ¼ 0.19 vs. E169K-PKI) (Fig. 2C).
Mutation E169K in JPH2 increases spontaneous SR
Ca2D leakage in atrial myocytes. To determine whether
the E169K mutation in JPH2 increased susceptibility toAF by altering intracellular Ca2þ handling, we assessed
the incidence of spontaneous SR Ca2þ release events in
isolated atrial myocytes. Atrial myocytes isolated from
E169K-PKI mice exhibited a signiﬁcantly increased inci-
dence of spontaneous Ca2þ waves following a 1-Hz pacing
train (3.67  1.47/min) compared with myocytes fromWT-
PKI and A399S-PKI mice (0.33  0.33/min and 0.11 
0.11/min, respectively; p < 0.05) (Figs. 3A and 3C). These
cell-wide spontaneous Ca2þ waves can directly activate
NCX, trigger DADs, and cause triggered activity associated
with AF (4).
To gain more insight into the mechanisms of altered
SR Ca2þ release, we quantiﬁed the incidence of spontaneous
subcellular Ca2þ sparks (Fig. 3B). The Ca2þ spark frequency
was signiﬁcantly increased in atrial myocytes from E169K-
PKI mice (5.86  0.88/min) compared with those from
WT-PKI mice and A399S-PKI mice (3.74  0.45 and
3.48  0.87 respectively; p < 0.05) (Figs. 3B and 3D).
This abnormal diastolic Ca2þ leakage produced reduced
SR Ca2þ load in E169K-PKI mice compared with
WT-PKI mice (Online Fig. 4). Thus, our data show that
the E169K mutation in JPH2 leads to abnormal SR Ca2þ
release via RyR2, suggesting that the Ca2þ release channel
is less stable in mice with the E169K but not the A399S
JPH2 mutant variant.
E169K mutation reduces JPH2-RyR2 binding. To gain
more insights into the mechanisms by which E169K-JPH2
Figure 3
Enhanced SR Ca2þ Leak in E169K-PKI But Not
A399S-PKI Mouse Myocytes
(A) Representative confocal line scan images and proﬁles show spontaneous cell-
wide Ca2þ waves in atrial myocytes from E169K-PKI mice following 1-Hz ﬁeld
stimulation. (B) Representative confocal line scan images show increased inci-
dence of Ca2þ sparks in atrial myocytes from E169K-PKI mice following 1-Hz ﬁeld
stimulation. (C, D) Graphs show quantiﬁcation of SCR and CaSpF. *p < 0.05.
CaSpF ¼ Ca2þ spark frequencies; SCR ¼ spontaneous Ca2þ release;
SR ¼ sarcoplasmic reticulum.
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2014potentially affects RyR2 activity, we ﬁrst assessed the amount of
JPH2 binding to RyR2. Immunoprecipitation using anti-RyR2
antibody was performed using cardiac lysates from NTg,
WT-PKI, E169K-PKI, and A399S-PKI mice (Fig. 4A).
Subsequent Western blotting for RyR2 and JPH2 revealed
signiﬁcantly reduced co-immunoprecipitation of E169K-
mutant JPH2 with RyR2 compared with WT-JPH2 and
A399S mutant JPH2 (Fig. 4B). These results suggest that the
E169K mutation in JPH2 speciﬁcally disrupts its binding
domain with RyR2.
JPH2 levels inversely correlate with atrial arrhythmogenesis
in mice. To determine whether there is an association
between reduced atrial JPH2 protein levels and AF
susceptibility, we studied 3 genetically modiﬁed mousemodels expressing different levels of JPH2 in the heart.
Tg mice overexpressing WT JPH2 (WT-Tg) had w2.9-
fold higher JPH2 protein levels than NTg mice
(Fig. 4C). Compared with NTg mice, cardiac-speciﬁc
knockdown mice (JPH2-KD) (10) exhibited w1.9-fold
lower JPH2 levels in the heart. When subjected to
rapid atrial burst pacing, WT-Tg mice were less suscep-
tible to pacing-induced AF compared with NTg mice,
whereas JPH2-KD mice were more susceptible (p ¼ 0.04
across the groups) (Fig. 4D). Thus, these experiments
demonstrated that susceptibility to AF in mouse models
is inversely correlated with atrial JPH2 protein levels.
These data suggest that reduced JPH2 levels might be
the culprit mechanism for RyR2 dysfunction and the
increased AF susceptibility identiﬁed in E169K-PKI
mice.
JPH2-derived peptide stabilizes RyR2-mediated SR
Ca2D release. To assess whether JPH2 binding to RyR2
modulates SR Ca2þ release, we synthesized a peptide cor-
responding to the 25 amino acids of the JPH2 region
that ﬂanks residue E169. Next, the JPH2 peptide was
added to permeabilized atrial myocytes from JPH2-KD
mice, in which JPH2 expression was reduced. Baseline
Ca2þ spark frequency in vehicle-treated JPH2 knockdown
was relatively high (8.2  0.6 sparks/100 mm/s) (Figs. 5A
and 5B). Addition of the JPH2-derived peptide signiﬁ-
cantly decreased the Ca2þ spark frequency in a dose-
dependent manner (1 mM peptide: 5.2  0.4; p < 0.01;
and 10 mM peptide: 0.48  0.27; p < 0.001 vs. vehicle).
A control peptide (10 mM) in which the same 25 amino
acids were scrambled did not affect the Ca2þ spark
frequency (9.4  1.5; p ¼ NS vs. vehicle).
Furthermore, single-channel measurements in planar
lipid bilayers revealed a high average Po of RyR2 channels
isolated from JPH2-KD mice (0.12  0.048), which was
signiﬁcantly reduced after the addition of JPH2 peptide
(0.048  0.024; p < 0.05) (Figs. 5C and 5D). In contrast,
the addition of JPH2 peptide did not change the average
Po of RyR2 isolated from alpha myosin heavy chain
(aMHC)-mER-Cre-mER (MCM) control mice (0.032 
0.02 vs. 0.024  0.01; p ¼ NS). The speciﬁcity of the
peptide effects was conﬁrmed by the demonstration that the
scrambled peptide did not have a signiﬁcant effect on the
Po of RyR2 isolated from both MCM control mice and
JPH2-KD mice (Online Fig. 5). Taken together, these data
strongly suggest that JPH2, in particular the domain con-
taining the E169 residue, are critical for stabilization of
RyR2 channel activity.
Decreased JPH2/RyR2 ratio in patients with paroxysmal
AF correlates with enhanced SR Ca2þ leak. In view of the
inverse correlation between atrial JPH2 levels and AF
susceptibility in Tg mice, we set out to determine whether
changes in JPH2 and RyR2 expression levels might occur in
more common AF patients without either JPH2 mutations
or HCM. Overall, the pAF and sinus rhythm patient
cohorts included mostly elderly patients with signiﬁcant
Figure 4
JPH2 E169K Mutant But Not A399S Mutant Reduces JPH2-RyR2 Binding, and JPH2 Levels Inversely Correlate
With AF Inducibility
(A) Western blots show reduced JPH2 co-immunoprecipitation following RyR2 pull-down from cardiac lysates of E169K-PKI mouse heart compared with those of WT-PKI, A399S-PKI,
and NTg mice. (B) Graph shows quantiﬁcation of JPH2 co-immunoprecipitated with RyR2 pull-down. (C)Western blots show total JPH2 levels compared with GAPDH in atria frommice
that overexpressed higher cardiac JPH2 levels (WT-Tg), control non-Tg Mer-Cre-Mer (MCM) mice with normal JPH2 levels (NTg), or MCM-shJPH2 knockdown mice with reduced cardiac
JPH2 levels (JPH2-KD). Graphs show JPH2 levels normalized to GAPDH in these three groups on a logarithmic scale. (D) Stacked bar graph shows AF incidence after atrial burst pacing
in the 3 groups of mice. Numbers of mice per group are shown inside bars. *p < 0.05, **p < 0.01, ***p < 0.001. AF ¼ atrial ﬁbrillation.
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2015co-morbidities including ischemic and valvular heart disease,
diabetes mellitus, hypertension, and hyperlipidemia (Online
Table 1). There were no signiﬁcant differences between pa-
tient characteristics, except for a slightly higher average age in
the pAF group. However, there was no signiﬁcant correlation
between age and atrial JPH2 protein levels (Online Fig. 6).
Western blotting revealed increased RyR2 but unaltered
JPH2 levels in atrial tissues from patients with pAF compared
with those in sinus rhythm, resulting in a signiﬁcantly lower
JPH2/RyR2 ratio (Figs. 6A to 6D). In contrast, the protein
levels of SERCA2a and phospholamban (PLN), Ca2þ cycling
proteins involved in Ca2þ resequestration into the SR, were
unchanged (Figs. 6E and 6G).
Whereas several recent studies have documented
profound changes in SR Ca2þ handling in atrial myocytes
from patients with chronic AF, much less is known about
Ca2þ handling in paroxysmal AF. Therefore, atrial
myocytes were isolated from right atrial samples from
pAF patients and control individuals in sinus rhythm. In
the presence of high intracellular Ca2þ concentrations,
atrial myocytes from pAF patients were signiﬁcantly more
likely to exhibit spontaneous SR Ca2þ release (SCR)
events compared with myocytes from sinus rhythm
patients (Figs. 7A and 7B). In addition, the frequency of
SCR was increased in atrial myocytes from patients in
pAF, and there was a trend toward a shorter interval
between the ﬁnal regularly triggered Ca2þ transient andﬁrst SCR (Fig. 7C). There was also a nonsigniﬁcant
increase in the amplitude of the SCR in patients with
pAF compared to that in sinus rhythm patients. Finally,
the amplitude of the NCX current induced by SCR was
approximately 2-fold higher in atrial myocytes from
patients with pAF than in those in sinus rhythm
(Fig. 7D). Thus, reduced atrial JPH2 levels per RyR2
channel correlated with an increased incidence of spon-
taneous SR Ca2þ release events and enhanced proar-
rhythmogenic NCX currents in atrial myocytes from
patients with pAF.
Discussion
This study describes the ﬁrst example of a defect in
a structural protein (i.e., junctophilin-2) that causes atrial
arrhythmias due to perturbed Ca2þ handling. Speciﬁcally,
the inherited mutation E169K in JPH2 affects RyR2-
mediated SR Ca2þ release from the SR, causing triggered
activity and supraventricular arrhythmias in both patients
and mice with the JPH2 E169K mutation in the heart.
Biochemical studies revealed that the E169K mutation
impairs binding of JPH2 to RyR2. This molecular defect
was not observed for the JPH2 mutation A405S identiﬁed in
HCM patients without atrial arrhythmias. Our studies
identiﬁed the residue E169 as being part of a critical domain
within JPH2 that inhibits RyR2 channel activity.
Figure 5 JPH2-Derived Small Peptide Stabilizes RyR2-Mediated SR Ca2þ Leak in Atrial Myocytes From JPH2 Knockdown Mice
(A) Representative confocal line scans show spontaneous Ca2þ sparks recorded from permeabilized atrial myocytes treated with vehicle only (upper left), JPH2 peptide at 1 mM
(upper right), JPH2 peptide at 10 mM (bottom left), and scrambled control peptide (10 mM; bottom right). (B) Graph shows CaSpF, which was signiﬁcantly decreased by JPH2-
derived peptide but not by scrambled control peptides. *p < 0.05,**p < 0.01, ***p < 0.001. Numbers indicate number of cells (number of mice). (C) Representative planar
lipid bilayer RyR2 single-channel tracings from Mer-Cre-Mer (control) and JPH2 knockdown (JPH2-KD) mice at baseline (top) and with the addition of JPH2 peptide (bottom). (D)
Graph shows signiﬁcant increase in RyR2 Po in JPH2-KD versus control and signiﬁcant reduction in RyR2 Po with the addition of JPH2 peptide in JPH2-KD mice. p < 0.05.
CaSpF ¼ Ca2þ spark frequency; Po ¼ open probability; SR ¼ sarcoplasmic reticulum.
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2016Furthermore, reduced amounts of functionally intact (WT)
JPH2 per RyR2 channel, resulting in a loss of JPH2-
mediated stabilization of RyR2 may also contribute to
arrhythmogenesis in patients with paroxysmal AF (15).
Recent studies have shown that genetic mutations in
JPH2 are a rare cause of HCM (12,13,16). The ﬁrst JPH2
variant speciﬁcally linked to cardiac arrhythmias, E169K,
was identiﬁed in an HCM index patient with atypical
disease features, most notably juvenile-onset paroxysmal
AF, supraventricular arrhythmias, and paroxysmal SA
blocks, which are rarely seen in patients with HCM in the
absence of signiﬁcant atrial remodeling (17). In contrast, AF
is more commonly observed in HCM with increasing age
and/or atrial dilatation (17). Thus, these clinical ﬁndings
suggested that the E169K mutation in JPH2 promoted
atrial arrhythmias independently of the mechanism related
to HCM formation caused by other JPH2 variants,
including A405S (A399S in mice). Indeed, our ﬁndings
revealed that E169K-PKI mice were susceptible to AF
without evidence of structural cardiomyopathy at the age of
2 months. Moreover, A399S-PKI mice did not develop
a susceptibility to AF, similarly to WT-PKI mice. There-
fore, it is likely that the proarrhythmogenic effects of the
E169K mutation are due to the reduced binding of E169K-
JPH2 to RyR2, whereas HCM development likely involves
other cellular mechanisms that remain to be explored in
future studies.The E169K mutation in JPH2 is located in a ﬂexible
“joining domain” connecting 2 sets of membrane-binding
domains that attach JPH2 to the sarcolemma (16).
Because the RyR2 channel is large and predicted to occupy
most of the dyadic space between the sarcolemma and SR,
the joining domain is a prime candidate to mediate the
physical interaction of JPH2 with RyR2 (18). The region
around residue E169 is highly conserved in evolution,
highlighting the functional importance of this domain (16).
Indeed, our data using a small JPH2-derived peptide con-
taining the E169 residue was able to alter RyR2 functional
activity, indicating direct channel modulation. Furthermore,
co-immunoprecipitation experiments revealed that mutation
E169K greatly reduced JPH2 binding to RyR2, whereas
another HCM-associated mutation A399S (in mice) did not
affect RyR2 binding. The effects of the peptide centered
around the E169 residue were very speciﬁc, as a scrambled
peptide containing the same amino acids did not inhibit
RyR2 in single-channel experiments, nor did it suppress
Ca2þ sparks in atrial myocytes.
JPH2 was ﬁrst identiﬁed as a structural protein within the
Ca2þ-release unit (CRU) that anchors the SR membrane to
the plasma membrane (11). The current study uncovered an
important additional cellular role of JPH2 in car-
diomyocytes, namely regulation of RyR2-mediated SR Ca2þ
release. Mutation E169K in JPH2, which interferes with
RyR2 modulation, caused increased SR Ca2þ leakage
Figure 6 Reduced JPH2/RyR2 Ratios in Patients With Paroxysmal AF
Representative Western blots (A) and graphs (B, C) show RyR2 and JPH2 protein levels normalized to CSQ in atria from patients in sinus rhythm (SR) and paroxysmal AF (pAF).
(D) Ratio of JPH2-to-RyR2 levels in human atria. Representative Western blots (E) and bar graphs (F, G) showing SERCA2a and PLB levels normalized to CSQ. AF ¼ atrial
ﬁbrillation; CSQ ¼ calsequestrin.
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2017(Fig. 3), which is similar to what we recently demonstrated
with knockdown of JPH2 in ventricular myocytes (10). It is
theoretically possible that the JPH2 mutation also affects
regulation of other known JPH2-binding partners within
the CRU such as the L-type Ca2þ channel (LTCC) and the
transient-receptor potential channel, subfamily C, member 3
(TRPC3) (15,19,20). However, it is unlikely that the
E169K mutation affects the LTCC function, as ICa was not
altered in atrial myocytes isolated from E169K-PKI mice
(data not shown). Interestingly, it has been shown that in
skeletal muscle, mutation S165F in JPH2 can block
a potential PKC phosphorylation site, which in turn might
reduce binding of JPH2 with TRPC3 (15). However, at this
time it is unknown whether the JPH2 mutation E169K
affects gating of the TRPC3 Ca2þ channel. Our peptide
data suggest that JPH2 strongly regulates RyR2-mediated
Ca2þ release, and that the E169K mutation decreases
binding to RyR2. Thus, it is very likely that the cellular
mechanisms underlying arrhythmogenesis caused by the
E169K mutation involve reduced JPH2 binding to RyR2,
diastolic SR Ca2þ release, and arrhythmogenic after-
depolarizations leading to atrial arrhythmias.
A growing body of literature suggests that altered
intracellular Ca2þ handling is a key contributor to AF, in
particular ectopic activity associated with AF induction
(21,22). Ectopic activity is caused by abnormal spontaneous
action potentials that can result from DADs induced by
diastolic SR Ca2þ release (4,9,22,23). However, the
mechanisms by which RyR2 exhibit increased sensitivity to
Ca2þ-mediated activation have been only partially under-
stood and likely involve hyperphosphorylation of RyR2 in
patients with chronic AF (4,9). The present study extendsthese previous ﬁndings by showing that another cellular
defect, namely reduced JPH2 levels per RyR2 channel
could also contribute to RyR2 dysfunction, especially in
patients with pAF.
Our current data suggest that a lower JPH2/RyR2 ratio
may promote increased RyR2-mediated SR Ca2þ release
events that are likely to cause proarrhythmic DADs in pAF
patients. Similar ﬁndings have been reported for another
accessory subunit that stabilizes RyR2, namely FK506-
binding protein 12.6 (FKBP12.6). Patients with chronic
AF exhibit a reduced FKBP12.6:RyR2 ratio (23). In mice,
reduced FKBP12.6 levels predispose to both ventricular
and atrial arrhythmias due to an increased sensitivity to
Ca2þ-mediated activation of RyR2 resulting in spontaneous
Ca2þ release events and triggered activity (9,24,25).
Finally, studies in atrial cardiomyocytes from both mouse
models and patients with chronic AF have established that
aberrant RyR2-mediated SR Ca2þ release events activate
NCX, which causes DADs, providing the trigger for AF
(4,8,9). Future studies using JPH2 peptides might prove
whether loss of JPH2-mediated RyR2 stabilization is caus-
ally linked to arrhythmogenic SR Ca2þ release events in
patients with AF.
Study limitations. The link between the E169K mutation
in JPH2 and atrial arrhythmias is based on 2 patients with
the unusual presentation of atrial arrhythmias and HCM.
Unfortunately, there were no additional family members
available for genotyping. On the other hand, the association
of HCM and supraventricular arrhythmias at a young age
and prior to signiﬁcant atrial remodeling is rather unique and
not seen in carriers of the A405S mutation or other previ-
ously published JPH2 mutations linked to HCM (12,13).
Figure 7 Enhanced Proarrhythmic Ca2þ Release Events in Patients With Paroxysmal AF
(A) Representative Ca2þ transient and membrane current (Im) tracings from isolated atrial myocytes from patients in sinus rhythm and those in pAF following 1 min of pacing at
0.5 Hz. (B) Graph shows incidence of SCR events. (C) Frequency (left), latency (middle), amplitude (right) of SCR. (D) Amplitude of SCR-mediated NCX current. *p < 0.05,
**p < 0.01. Numbers represent number of cells/number of patients. AF ¼ atrial ﬁbrillation; NCX ¼ Naþ/Ca2þ exchanger; pAF ¼ paroxysmal atrial ﬁbrillation; SCR ¼ spon-
taneous Ca2þ release.
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2018Although knock-in mice can be used to study the effects
of point mutations on protein function, our repeated efforts
to generate E169K knock-in mice failed thus far. However,
we were able to establish E169K mutant mice with physi-
ological JPH2 levels in the heart by crossing E169K-Tg
mice with MCM-shJPH2 knockdown mice (10). Thus,
our pseudoknock-in mouse models serve as an adequate
model when more traditional knock-in mice are not available
or feasible.
The E169K-PKI mice did not develop spontaneous atrial
arrhythmias, unlike the human carriers of the E169K
mutation in JPH2. This is not surprising, as it is well
established that mice are relatively resistant to developing
AF unless there is gross atrial remodeling or dilation.
In other mouse models of genetic variants that cause
spontaneous AF in humans, we did not observe spontaneous
AF although such mutant mice were vulnerable to pacing-
induced arrhythmias (8,26). Although it is well accepted
that an enhanced susceptibility to AF in mice is an
approximate validation of a genetic variant that causes
spontaneous AF in humans, using mice as an experimental
model is a clear general limitation.
Finally, we used only right atrial tissue samples collected
from the right atrial appendage of humans with paroxysmal
AF. Although it is well established that ectopic activity often
arises from the pulmonary vein region, there is also evidence
for highly frequent focal sources in the right atrium in up to
33% of patients (27). Our ﬁnding of reduced JPH2 levels perRyR2 channel might not apply to other atrial regions or the
left atrium. On the other hand, analysis of right atrial tissue
samples and myocytes has proven to be useful and conﬁrmed
the presence of increased Ca2þ sparks and remodeling of
Ca2þ handling proteins in patients with paroxysmal and
chronic AF (4,28,29).
Conclusions
We describe a novel mechanism by which the JPH2 E169K
mutation can cause atrial arrhythmias as a result of defective
RyR2-mediated SR Ca2þ release events. The inherited
mutation E169K in JPH2 disrupts the binding of mutant
JPH2 to RyR2 and destabilizes RyR2, thereby increasing SR
Ca2þ leak and the inducibility of AF in mice. These
mechanisms are only observed in E169K mutant mice and
not in another HCM-associated (A399S) mutant mouse,
suggesting that the mechanisms underlying HCM-related
ventricular remodeling are distinct and unrelated to RyR2
destabilization. Interestingly, patients with paroxysmal AF
(nongenetic and not associated with HCM) exhibit
decreased atrial JPH2 levels per RyR2 channel, suggesting
that a similar mechanism of RyR2 destabilization due to
a relative depletion of JPH2 could be involved in a much
larger population of patients with paroxysmal AF. Our work
suggests that future studies are warranted to explore whether
JPH2-mediated stabilization of RyR2 might represent
a novel therapeutic target for atrial arrhythmias. Speciﬁcally,
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2019with the emergence of cell-penetrating peptides and small
peptide therapies, it may be possible to develop a targeted
therapy to reduce atrial arrhythmias (30).
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APPENDIX
For and expanded methods section, and supplemental tables and ﬁgures,
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